<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlos Roberto Ribeiro de Carvalho, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronaldo A Kairalla, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruno Guedes Baldi, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joyce S Lee, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sjögren's disease (SjD) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function and associated with lymphocytic infiltration of exocrine glands, especially the lacrimal and salivary glands. In addition to causing dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), SjD can affect extraglandular organ systems including the skin, lung, heart, kidney, neural, and hematopoietic systems.
        </p>
        <p>
         The clinical manifestations, evaluation, and diagnosis of interstitial lung disease (ILD) in SjD will be reviewed here. The clinical manifestations, classification, criteria for diagnosis, and pathogenesis of SjD and the management of interstitial lung disease (ILD) associated with SjD (SjD-ILD) are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">
          "Clinical manifestations of Sjögren’s disease: Extraglandular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H346756766">
         <span class="h1">
          NOMENCLATURE
         </span>
        </p>
        <p class="headingAnchor" id="H87632609">
         <span class="h2">
          American-European criteria for SjD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) criteria for the diagnosis of SjD are listed in the table  (
         <a class="graphic graphic_table graphicRef117432" href="/z/d/graphic/117432.html" rel="external">
          table 1
         </a>
         ). These criteria were not developed for clinical practice and not every patient who receives a diagnosis of SjD fulfills the proposed criteria. The clinical diagnosis of SjD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Classification criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary Sjögren's disease
         </strong>
         – Primary Sjögren's disease (pSjD) is diagnosed only when all other systemic rheumatic diseases are excluded; it predominantly affects women between 50 and 70 years of age. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary Sjögren's disease
         </strong>
         – Secondary Sjögren's disease (sSjD) refers to SjD that occurs in association with another connective tissue disease, most commonly rheumatoid arthritis, but also including systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, and inflammatory myositis. ILD that develops in a patient with sSjD is evaluated based on the primary rheumatic disease, rather than as a manifestation of sSjD. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2427923025">
         <span class="h1">
          TYPES OF INTERSTITIAL LUNG DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The types of SjD-ILD largely mirror the idiopathic interstitial pneumonias [
         <a href="#rid1">
          1-5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonspecific interstitial pneumonia (NSIP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Usual interstitial pneumonia (UIP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryptogenic organizing pneumonia (COP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoid interstitial pneumonia (LIP)
        </p>
        <p>
        </p>
        <p>
         Follicular bronchiolitis can be seen on its own or in the context of NSIP or OP. Nodular lymphoid hyperplasia, primary pulmonary lymphoma, and diffuse interstitial amyloidosis are much less common [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         ILD is the most common pulmonary abnormality in primary Sjögren's disease (pSjD) [
         <a href="#rid5">
          5,9-13
         </a>
         ]. SjD-ILD is more common in women than men and has a median age of onset of 60 years [
         <a href="#rid14">
          14,15
         </a>
         ]. ILD appears more common among patients with pSjD than in those with secondary Sjögren's disease (sSjD), although it tends to be less severe than the ILD associated with sSjD or other rheumatic diseases [
         <a href="#rid11">
          11,16,17
         </a>
         ]. The greater severity of ILD in sSjD may be due to the simultaneous effects of lung involvement due to SjD and the associated rheumatic disease (eg, rheumatoid arthritis, systemic lupus erythematosus) [
         <a href="#rid11">
          11
         </a>
         ]. SjD-ILD is most common in patients who have both glandular and extraglandular manifestations of SjD [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         The proportion of patients with SjD who develop ILD at some point is estimated to be 10 to 20 percent, although reports describe variable frequencies [
         <a href="#rid10">
          10,16,19-21
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a large review conducted by the European Alliance of Associations for Rheumatology (EULAR)-SjD task force including 273 articles, comprising 4897 patients of pSjD fulfilling the 2002 American European Consensus Group definition, 16 percent (795) of the patients exhibited pulmonary involvement. Computed tomography (CT) scans available for 526 of these patients disclosed ground-glass appearance or interstitial changes in 50 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 840 patients with pSjD identified by computerized chart review, ILD was noted in 104 (12 percent) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A series of 343 patients found evidence of pulmonary involvement in 9 percent based on reported symptoms, chest radiographs, and pulmonary function tests [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a longitudinal study of 105 patients with pSjD who were followed at a referral center, ILD developed in 10 percent after one year and in 20 percent after five years [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Less commonly, ILD can be the presenting manifestation of SjD. Among a cohort of patients with various diffuse ILDs, a surprisingly high prevalence of objective xerostomia (17 percent) was reported [
         <a href="#rid24">
          24
         </a>
         ]. Definite SjD was diagnosed in 5.4 percent of the cohort, suggesting that undiagnosed SjD may be a more common cause of ILD than previously noted [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Onset of ILD is typically 5 to 10 years after the onset of SjD, although lung disease may occasionally precede the diagnosis of SjD [
         <a href="#rid24">
          24,25
         </a>
         ]. The symptoms and signs of SjD-ILD depend on the type and severity of lung parenchymal and lower airway involvement [
         <a href="#rid9">
          9-12,16,19-21,26,27
         </a>
         ].
        </p>
        <p>
         In a review of 260 reported patients with primary Sjögren's disease (pSjD) and lung involvement, the clinical features included dyspnea (62 percent), cough (54 percent), sputum (14 percent), chest pain (5 percent), and fever (2 percent) [
         <a href="#rid3">
          3
         </a>
         ]. Clubbing is rare [
         <a href="#rid2">
          2
         </a>
         ]. The severity of respiratory symptoms ranges from subclinical lung disease to mild cough or dyspnea to slowly progressive respiratory insufficiency, although mild dyspnea on exertion is most common [
         <a href="#rid1">
          1,17,28
         </a>
         ].
        </p>
        <p>
         Patients with lymphoid interstitial pneumonia (LIP) associated with SjD are rarely asymptomatic; cough (71 percent) and dyspnea (61 percent) are the most common symptoms, but weight loss, fevers, and pleuritic chest pain can also be present. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia", section on 'Symptoms'
         </a>
         .)
        </p>
        <p>
         Occasionally, patients with SjD-ILD will report Raynaud phenomenon, arthralgias, fever, or rash. The extrapulmonary symptoms of SjD are described separately. (See
         <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">
          "Clinical manifestations of Sjögren’s disease: Extraglandular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease"
         </a>
         .)
        </p>
        <p>
         Bibasilar crackles are noted on physical examination in approximately 60 percent of patients with SjD-ILD [
         <a href="#rid2">
          2,22,29
         </a>
         ]. Cutaneous vasculitis occurs in approximately 10 percent of patients with SjD and can present with urticarial lesions, purpura, or punctate erosions. The extrapulmonary signs of SjD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">
          "Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Extraglandular organ involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H346757511">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic approach to suspected ILD in patients with SjD follows the general approach to interstitial lung disease; infectious, drug-induced, inhalational, and cardiovascular causes must be excluded, as with any new diagnosis of ILD. Because of the high frequency of lung involvement in SjD and the potential for sarcoidosis to mimic SjD, we typically obtain a chest radiograph as part of the initial evaluation of a patient with SjD. If ILD is suspected on the basis of cough, dyspnea, audible crackles, or an abnormal chest radiograph, we obtain complete pulmonary function tests and a high-resolution computed tomography (HRCT) scan. Further evaluation is based on the results of these tests and collaboration with the patient’s rheumatic disease specialist. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Laboratory
         </span>
         <span class="headingEndMark">
          —
         </span>
         When ILD is suspected in a patient with SjD, we usually confirm the original diagnosis of SjD by reviewing or obtaining serologic studies such as the antinuclear antibody, anti-Ro/SSA (preferably as separate components anti-Ro52 and anti-Ro60), anti-La/SSB antibodies, rheumatoid factor, erythrocyte sedimentation rate [ESR], and immunoglobulin quantification. The laboratory evaluation and diagnosis of SjD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems", section on 'Sjögren's disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems", section on 'Anti-Ro60 versus anti-Ro52 antibodies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">
          "Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Autoantibodies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Serologic and other laboratory testing'
         </a>
         .)
        </p>
        <p>
         Patients with ILD related to primary Sjögren's disease (pSjD) or secondary Sjögren's disease (sSjD) tend to have variable patterns of antibody positivity. As an example, in a series of 14 patients with pSjD-associated ILD documented on lung biopsy, antinuclear antibodies (ANA) were noted in six, anti-Ro/SSA antibody in eight, and anti-La/SSB antibody in two [
         <a href="#rid22">
          22
         </a>
         ]. Similar findings were noted in 13 patients with ILD and SjD (diagnosed by a positive minor salivary gland biopsy): ANA and anti-Ro/SSA antibodies were positive in eight; rheumatoid factor (RF) in three; and anti-La/SSB antibody in two [
         <a href="#rid30">
          30
         </a>
         ]. While no serologic marker has been identified that clearly predicts ILD in SjD, some studies have found an increased risk of ILD associated with anti-Ro52 antibodies [
         <a href="#rid31">
          31,32
         </a>
         ]. Among 68 patients with pSjD, ILD was noted in 42 percent of the anti-Ro52 positive patients compared with 16 percent of the anti-Ro52 negative patients [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Limited data are available to assess whether specific antibodies correlate with disease severity [
         <a href="#rid29">
          29,32
         </a>
         ]. A series of 30 patients noted that anti-Ro/SSA antibody positivity correlated with a significantly lower diffusing capacity than anti-Ro/SSA antibody negativity [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         If IgG4-related disease is suspected as an alternative diagnosis due to lacrimal and salivary gland enlargement, immunoglobulin subclass levels are obtained looking for an elevated level of IgG4. (See
         <a class="local">
          'IgG4-related disease'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Chest imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chest radiograph is usually part of the initial evaluation of patients with SjD due to the frequency of lung involvement and as sarcoidosis is in the differential diagnosis. If respiratory symptoms develop or worsen, imaging is repeated, usually with HRCT.
        </p>
        <p class="headingAnchor" id="H17659888">
         <span class="h3">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         The chest radiograph in patients with SjD-ILD typically shows a fine reticular or nodular pattern with basilar prominence, but may be normal or less commonly show cysts or pleural abnormalities [
         <a href="#rid4">
          4,10,33
         </a>
         ]. Retrospective series of patients with either pSjD or sSjD have noted abnormalities on chest radiograph in 10 to 20 percent [
         <a href="#rid10">
          10,34
         </a>
         ]; the rate of radiographic abnormalities may be higher in patients with pSjD than sSjD [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17659895">
         <span class="h3">
          High-resolution computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         HRCT is more sensitive for identifying interstitial lung disease than a chest radiograph [
         <a href="#rid28">
          28,36,37
         </a>
         ]. In a series of 37 patients with SjD and normal chest radiographs, 25 (64 percent) had abnormalities on HRCT [
         <a href="#rid29">
          29
         </a>
         ]. A separate study found abnormalities suggestive of interstitial lung disease on CT in 34 percent of patients with pSjD, while the chest radiograph was abnormal in only 14 percent [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
         A variety of HRCT patterns have been reported in SjD-ILD [
         <a href="#rid3">
          3,22,37-40
         </a>
         ]. In a series of 60 patients with pSjD-associated ILD, HRCT abnormalities included ground-glass attenuation (92 percent), subpleural small nodules (78 percent), nonseptal linear opacities (75 percent), interlobular septal thickening (55 percent), bronchiectasis (38 percent), and cysts (30 percent) [
         <a href="#rid38">
          38
         </a>
         ]. Bronchial wall thickening and pleural irregularities are less frequently noted [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The frequency of each pattern depends on the characteristics of the population studied. As an example, among four studies of symptomatic patients with ILD, the frequency of nonspecific interstitial pneumonia patterns ranged from 20 to 60 percent [
         <a href="#rid1">
          1,37,41,42
         </a>
         ]. In two studies of asymptomatic patients, 8 percent had HRCT findings consistent with pulmonary fibrosis (honeycombing) [
         <a href="#rid28">
          28,37
         </a>
         ]. In a separate series, honeycombing was almost four times more common in sSjD as compared with pSjD, likely due to the presence of usual interstitial pneumonia (UIP) in patients with rheumatoid arthritis. (See
         <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">
          "Interstitial lung disease in rheumatoid arthritis", section on 'Pathologic patterns'
         </a>
         .)
        </p>
        <p>
         In general, HRCT is as reliable in predicting the histopathology of ILD in rheumatic disease as in the idiopathic ILDs  (
         <a class="graphic graphic_table graphicRef60070" href="/z/d/graphic/60070.html" rel="external">
          table 2
         </a>
         ). HRCT patterns associated with individual types of ILD in SjD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonspecific interstitial pneumonia (NSIP)
         </strong>
         – NSIP is associated with patchy ground-glass attenuation and intralobular reticulation with a lower lobe predilection. Traction bronchiectasis may be present and, occasionally, small areas of subpleural honeycombing. (See
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia", section on 'Chest imaging studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Usual interstitial pneumonia
         </strong>
         <strong>
          (UIP)
         </strong>
         – The characteristic HRCT appearance of UIP is increased reticular markings in a basilar and peripheral distribution and, as the disease progresses, areas of subpleural honeycombing. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoid interstitial pneumonia (LIP) and follicular bronchiolitis
         </strong>
         – The HRCT findings in LIP include ground-glass attenuation, centrilobular and subpleural nodules, septal thickening, reticular opacities, bronchial/bronchiolar thickening, and thin-walled cysts  (
         <a class="graphic graphic_diagnosticimage graphicRef65519" href="/z/d/graphic/65519.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef89082" href="/z/d/graphic/89082.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid28">
          28,41,43
         </a>
         ]. In some cases, ground-glass attenuation is more prominent  (
         <a class="graphic graphic_diagnosticimage graphicRef112799" href="/z/d/graphic/112799.html" rel="external">
          image 3
         </a>
         ); in other cases, the cystic changes predominate  (
         <a class="graphic graphic_diagnosticimage graphicRef113742" href="/z/d/graphic/113742.html" rel="external">
          image 4
         </a>
         ), such that diffuse cystic lung disease can be a presenting manifestation of SjD [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia", section on 'Chest imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Occasionally, patients have thin-walled cysts in the absence of other lung parenchymal abnormalities [
         <a href="#rid15">
          15,44
         </a>
         ]. In these patients, the cysts tend to be lower lobe predominant and peribronchovascular, and may range in number from 1 to almost 100 [
         <a href="#rid44">
          44
         </a>
         ]. Cystic lung disease is variably associated with anti-Ro-SSA antibodies [
         <a href="#rid15">
          15
         </a>
         ] or anti-La-SSB antibodies [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Laboratory'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follicular bronchiolitis
         </strong>
         – Follicular bronchiolitis can be present alone or in combination with LIP or NSIP. HRCT features include centrilobular and peribronchial nodules 1 to 12 mm in diameter and thickening of the bronchial/bronchiolar walls. (See
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults", section on 'Follicular bronchiolitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organizing pneumonia (OP)
         </strong>
         – The HRCT findings of SjD-associated OP include consolidative and ground-glass opacities, in addition to centrilobular nodules and tree-in-bud opacities [
         <a href="#rid2">
          2,45-47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Computed tomographic (CT) scanning'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nodular lymphoid hyperplasia
         </strong>
         – Pulmonary nodular lymphoid hyperplasia typically presents with a solitary mass or nodule, but can present with multiple nodules or as an area of ground-glass opacity or parenchymal consolidation with an air bronchogram [
         <a href="#rid7">
          7,26,48
         </a>
         ]. The nodules are often subpleural, but can be peribronchial [
         <a href="#rid8">
          8
         </a>
         ]. Mediastinal and hilar lymphadenopathy and pleural effusions are typically absent. (See
         <a class="local">
          'Nodular lymphoid hyperplasia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary nodular amyloidosis
         </strong>
         – In the rare patients with SjD-associated amyloidosis, HRCT findings include diffuse nodules, cystic lesions, focal consolidation, and diffuse septal thickening [
         <a href="#rid49">
          49,50
         </a>
         ]. (See
         <a class="local">
          'Pulmonary nodular amyloidosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/131094.html" rel="external">
          "Pleuropulmonary manifestations of amyloidosis", section on 'Nodular pulmonary amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4179668582">
         <span class="h3">
          Positron emission tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fluorodeoxyglucose-positron emission tomography (FDG-PET) may demonstrate increased lung uptake in certain types of SjD-associated lung disease. In a study that included 10 patients with SjD-associated lung disease, FDG-PET revealed increased lung uptake of FDG in seven patients [
         <a href="#rid51">
          51
         </a>
         ]. Among those with increased FDG uptake, the SUVmax was less than 3 except in one patient with lymphoid interstitial pneumonia who had areas of consolidation with a SUVmax of 8. Two patients had nodular consolidations in the lungs with a higher SUVmax (6.5 and 12) than that associated with ILD; these lesions were found to be mucosa-associated lymphoid tissue (MALT) lymphoma.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) are obtained to evaluate respiratory symptoms, crackles on chest examination, or an abnormal chest radiograph. The main role of PFTs is to confirm the presence of abnormalities consistent with ILD and to assess the severity of respiratory impairment.
        </p>
        <p>
         Patients with SjD and diffuse parenchymal opacities on chest radiographs typically have a restrictive pattern on PFTs with a low diffusing capacity [
         <a href="#rid1">
          1,11,18,20,52-55
         </a>
         ]. In one study of 20 patients with pSjD, significant reductions in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), vital capacity, and diffusing capacity (transfer factor for carbon monoxide or diffusing capacity of carbon monoxide [DLCO]) were noted in 14, 12, and 10 patients, respectively [
         <a href="#rid17">
          17
         </a>
         ]. The combination of a restrictive defect and a low DLCO appears to be more common in pSjD than in sSjD [
         <a href="#rid11">
          11,18
         </a>
         ].
        </p>
        <p>
         Evidence of airways disease has been reported patients with pSjD [
         <a href="#rid11">
          11,28,43,55
         </a>
         ], but the frequency is variable [
         <a href="#rid18">
          18
         </a>
         ]. Based on one series, an obstructive pattern may be more common in sSjD [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H346757694">
         <span class="h2">
          Minor salivary gland biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, ILD is the presenting manifestation of pSjD and the presence of sicca symptoms is elicited during the evaluation of ILD [
         <a href="#rid30">
          30
         </a>
         ]. If serologic testing (anti-SSA/Ro and anti-SSB antibodies, ANA by an immunofluorescence assay, and rheumatoid factor) is nondiagnostic, a minor salivary gland biopsy may lead to a more precise diagnosis underlying SjD. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Salivary gland biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoalveolar lavage (BAL) cell count patterns in SjD are nonspecific, so the main role of BAL in a patient who is suspected of having SjD-ILD is to exclude other causes of diffuse parenchymal lung disease, such as eosinophilic pneumonia, infection, lymphangitic tumor, and hemorrhage. Thus, BAL is usually performed in patients with SjD and ILD when respiratory symptoms have an acute onset or are accompanied by a fever, hemoptysis, or peripheral eosinophilia. BAL results are not sufficient to differentiate SjD-ILD from sarcoidosis. The technique of BAL and the role of BAL in the diagnosis of interstitial lung disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         Increased numbers of BAL lymphocytes or neutrophils are common among patients with pSjD [
         <a href="#rid35">
          35,56
         </a>
         ]. However, data are conflicting about whether the degree of lymphocytosis or neutrophilia predicts the presence or severity of ILD. In a study of 23 patients with pSjD, those patients whose BAL contained greater than 15 percent lymphocytes were more likely to have pulmonary symptoms (cough and dyspnea), radiographic evidence of interstitial lung disease, and decreased pulmonary function than those whose BAL had less than 15 percent lymphocytes [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         BAL cell counts do not appear to have prognostic value in SjD-ILD, and it is unknown whether patients with subclinical disease based on BAL results will develop symptomatic pulmonary disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 18 patients with pSjD and an initial lymphocytic or mixed lymphocytic/neutrophilic BAL, chest radiographs and pulmonary function were virtually unchanged over two years [
         <a href="#rid42">
          42
         </a>
         ]. Of 14 patients with an initial lymphocytic BAL (&gt;15 percent lymphocytes), the BAL differential normalized in six. BAL neutrophilia was associated with a greater rate of reduction in the DLCO, than BAL lymphocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, a longer study (12 years) of 22 patients with pSjD found that only those patients with greater than 15 percent lymphocytosis in their BAL died [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 29 patients with pSjD who did not have pulmonary symptoms or chest radiograph abnormalities, elevated BAL lymphocytes or neutrophils were noted in 55 percent [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung biopsy is generally not necessary when evaluating patients with SjD and radiographic and/or physiologic evidence of ILD. The usual indications for lung biopsy are a suspicion of malignancy or an atypical HRCT pattern and worsening clinical and radiographic abnormalities. Circumscribed or nodular areas of consolidation that are persistent and not attributable to infection generally require histopathologic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Overview'
         </a>
         .)
        </p>
        <p>
         Depending on the location of the abnormality and local expertise, transbronchial or cryobiopsy, video-assisted thoracoscopic, or surgical lung biopsy may be performed. Transbronchial lung biopsy is helpful in the positive diagnosis of sarcoidosis or lymphangitic carcinomatosis, whereas a larger biopsy from video-assisted thoracoscopic or open thoracotomy is needed to differentiate the various types of ILD. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37940347">
         <span class="h3">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathology of the interstitial pneumonias commonly associated with SjD mirror the idiopathic interstitial pneumonias [
         <a href="#rid27">
          27
         </a>
         ], which are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p>
         In a review of 146 published cases with histopathology, 45 percent were NSIP, 16 percent were UIP, 15 percent were LIP, 7 percent OP, and the remaining 17 percent other pathologies [
         <a href="#rid3">
          3
         </a>
         ]. The features described in patients with SjD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonspecific interstitial pneumonia (NSIP)
         </strong>
         – NSIP is characterized by expansion of alveolar septa by a variably dense infiltrate of predominantly mononuclear inflammatory cells with or without associated fibrosis. Within the category of NSIP, three subsets have been described: a cellular pattern with a greater degree of interstitial inflammation, a more fibrotic pattern, and a mixed pattern  (
         <a class="graphic graphic_table graphicRef81034" href="/z/d/graphic/81034.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef75438" href="/z/d/graphic/75438.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef58583" href="/z/d/graphic/58583.html" rel="external">
          picture 2
         </a>
         ). The significance of these subsets is not entirely clear, although the more fibrotic pattern appears to be more common in pSjD [
         <a href="#rid59">
          59
         </a>
         ]. In a series of 20 patients with NSIP associated with pSjD, the fibrotic pattern of NSIP was noted in 19 and the cellular pattern in 1 [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia", section on 'Histopathology and interpretation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoid interstitial pneumonia (LIP)
         </strong>
         – LIP is characterized by an extensive proliferation of lymphoid cells (T and B) and varying numbers of plasma cells along the alveolar septae, often associated with follicular bronchiolitis  (
         <a class="graphic graphic_table graphicRef69805" href="/z/d/graphic/69805.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef53820" href="/z/d/graphic/53820.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef63982" href="/z/d/graphic/63982.html" rel="external">
          picture 4
         </a>
         ). Germinal centers and multinucleated giant cells with occasional noncaseating granulomas are also described  (
         <a class="graphic graphic_picture graphicRef63982" href="/z/d/graphic/63982.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef52227" href="/z/d/graphic/52227.html" rel="external">
          picture 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef75674" href="/z/d/graphic/75674.html" rel="external">
          picture 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lymphocytic infiltration is a characteristic of SjD manifestations throughout the body. In addition to LIP, several patterns of lymphocytic lung involvement have been described: LIP, follicular bronchiolitis, nodular lymphoid hyperplasia, and lymphoma. It is not clear whether there is an evolution from one lymphocytic pattern to another.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Usual interstitial pneumonia (UIP)
         </strong>
         – The histologic hallmark and chief diagnostic criterion for UIP is a heterogeneous appearance with alternating areas of normal lung, patchy interstitial inflammation, fibroblast foci, and honeycomb change. In patients with SjD and UIP, a greater degree of lymphocytic infiltration may be noted compared with idiopathic cases. The histopathologic pattern of UIP is more commonly seen in patients with sSjD associated with rheumatoid arthritis or systemic sclerosis, than in pSjD. Among 42 patients with pSjD and ILD, none had UIP on biopsy, although UIP had been suspected based on HRCT in four [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organizing pneumonia (OP)
         </strong>
         – The characteristic histopathologic lesions of organizing pneumonia include excessive proliferation of granulation tissue within small airways (proliferative bronchiolitis) and alveolar ducts, associated with chronic inflammation in the surrounding alveoli. Foci of organizing pneumonia can be seen in association with NSIP. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Histopathologic diagnosis of organizing pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follicular bronchiolitis
         </strong>
         – In follicular bronchiolitis, hyperplastic lymphoid follicles with reactive germinal centers are distributed along the bronchioles and can cause compression of the airway lumen  (
         <a class="graphic graphic_picture graphicRef63982" href="/z/d/graphic/63982.html" rel="external">
          picture 4
         </a>
         ). The lymphoid proliferation is generally limited to the peribronchiolar area, but may extend into the surrounding alveolar septa [
         <a href="#rid43">
          43,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nodular lymphoid hyperplasia
         </strong>
         – Nodular lymphoid hyperplasia (also known as follicular lymphoid hyperplasia and the outdated term pseudolymphoma) is characterized by mixed infiltrates of mature T and B lymphocytes and plasma cells with numerous germinal centers  (
         <a class="graphic graphic_picture graphicRef55114 graphicRef68369 graphicRef82569" href="/z/d/graphic/55114.html" rel="external">
          picture 7A-C
         </a>
         ). It has certain key features that are used to differentiate it from marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, including a well-circumscribed lesion, minimal lymphangitic spread, presence of polyclonal lymphocytes, absence of intranuclear inclusions, and absence of immunoglobulin heavy chain rearrangements [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4138280568">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with known SjD and suspected ILD, the first step is to exclude infectious, drug-induced, and cardiovascular causes, as with any new diagnosis of ILD (see
         <a class="local">
          'Evaluation'
         </a>
         above). The next step is to review the high-resolution computed tomography (HRCT), keeping in mind that SjD-ILD usually mirrors the main types of idiopathic interstitial pneumonia (eg, nonspecific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], lymphoid interstitial pneumonia [LIP], organizing pneumonia [OP]) and the HRCT pattern will often guide further evaluation [
         <a href="#rid1">
          1,2,22,30,35,61
         </a>
         ]. (See
         <a class="local">
          'Types of interstitial lung disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Interstitial pneumonias
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an HRCT pattern suggestive of NSIP or UIP, a presumptive diagnosis can often be made based on the symptom pattern (eg, gradually progressive cough and dyspnea), basilar crackles, and HRCT findings (eg, increased reticular markings, patchy ground-glass opacities, lower lobe predominance)  (
         <a class="graphic graphic_table graphicRef60070" href="/z/d/graphic/60070.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,2,62
         </a>
         ]. Atypical features, such as fever, rapidly progressive disease, hemoptysis, or a nodular or mass-like HRCT appearance, typically require further evaluation. (See
         <a class="local">
          'High-resolution computed tomography'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia"
         </a>
         .)
        </p>
        <p>
         While not typical, OP can mimic NSIP with patchy ground-glass opacities and increased reticular markings. As the treatment of ILD in SjD is dictated more by the disease extent, respiratory impairment, rate of progression, and extrapulmonary disease, a precise diagnosis for these overlapping radiographic presentations is usually not necessary.
        </p>
        <p class="headingAnchor" id="H2291933784">
         <span class="h2">
          Organizing pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with consolidative or mass-like opacities on HRCT, a diagnosis of OP typically requires a lung biopsy [
         <a href="#rid2">
          2,45,46,63
         </a>
         ]. Particularly in patients with SjD, it is important to exclude lymphoma, nodular lymphoid hyperplasia, and other lymphoproliferative processes. Due to the small sample size of transbronchial biopsies, a video-assisted transthoracic or surgical approach is preferred. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18332038">
         <span class="h2">
          Lymphoid interstitial pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         LIP is well-described in patients with SjD and a clinical diagnosis can often be made based on a combination of thin-walled, perivascular cysts associated with ground-glass opacities or poorly defined centrilobular or subpleural nodules [
         <a href="#rid44">
          44
         </a>
         ]. However, when LIP presents with consolidative nodular opacities, a biopsy is required to exclude lymphoma and other causes of lung nodules. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia", section on 'Pathologic findings'
         </a>
         and
         <a class="local">
          'Follicular bronchiolitis'
         </a>
         below.)
        </p>
        <p>
         When thin-walled air cysts raise the possibility of LIP, it is important to consider the possibility of other causes or mimics of cystic lung disease, such as pulmonary Langerhans histiocytosis or combined pulmonary fibrosis and emphysema, especially in current or former cigarette smokers. (See
         <a class="medical medical_review" href="/z/d/html/112259.html" rel="external">
          "Diagnostic approach to the adult with cystic lung disease", section on 'Parenchymal lucencies that may mimic cysts'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Follicular bronchiolitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of follicular bronchiolitis may be suspected in a patient with SjD on the basis of dyspnea and associated HRCT findings of centrilobular and peribronchial nodules, sometimes with a tree-in-bud pattern, or follicular bronchiolitis may be identified as an associated finding in a patient with NSIP or LIP [
         <a href="#rid22">
          22
         </a>
         ]. Follicular bronchiolitis is characterized by lymphoid hyperplasia of mucosa-associated lymphoid tissue (MALT), as described above. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults", section on 'Follicular bronchiolitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Nodular lymphoid hyperplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nodular lymphoid hyperplasia (NLH; also known as follicular lymphoid hyperplasia or the outdated term "pseudolymphoma") is more common among patients with primary SjD than other rheumatic diseases and requires a lung biopsy for diagnosis [
         <a href="#rid7">
          7,8,60,64-66
         </a>
         ]. The HRCT appearance of one or more nodular or mass-like consolidation with or without air bronchogram does not allow differentiation from organizing pneumonia, lymphoma, or other consolidative processes [
         <a href="#rid8">
          8
         </a>
         ]. NLH may regress, remain stable, or progress to frank lymphoma [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15723.html" rel="external">
          "Cutaneous T cell pseudolymphomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H371114514">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of ILD in SjD includes ILDs that present with sicca symptoms or salivary gland involvement (eg, sarcoidosis, IgG4-related systemic disease), ILDs related to the underlying rheumatic disease in patients with secondary Sjögren's disease (sSjD; eg, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis [scleroderma], inflammatory muscle disease), drug-induced pneumonitis, and unrelated ILDs (eg, hypersensitivity pneumonitis, eosinophilic pneumonia). The characteristics of ILD associated with these rheumatic diseases and the differential diagnosis of ILD in general are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">
          "Interstitial lung disease in rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Interstitial lung disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4304.html" rel="external">
          "Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">
          "Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2122641619">
         <span class="h2">
          Sjögren's disease and sarcoidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis can present with lacrimal and salivary gland involvement, as well as diffuse parenchymal lung disease. In addition, sarcoidosis can occur concomitantly with SjD. In one patient with SjD, for example, lung biopsy revealed a chronic noncaseating granulomatous inflammatory reaction with moderate lymphocytic infiltration of the surrounding alveoli, a finding that led to the concurrent diagnosis of sarcoidosis [
         <a href="#rid58">
          58
         </a>
         ]. A literature review of histopathologic changes in the exocrine glands of 53 patients with sarcoidosis noted coexistence of sarcoidosis and SjD in 28 cases; in the remaining 25 patients, sarcoidosis mimicked SjD [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
         Potential explanations for the simultaneous occurrence of both disorders include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The two diseases share a common immunologic abnormality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The derangement caused by one disorder may result in the other
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The finding is coincidental
        </p>
        <p>
        </p>
        <p>
         Possible support for the first hypothesis comes from a study of lung biopsy specimens from 10 patients with SjD [
         <a href="#rid60">
          60
         </a>
         ]. There were significant elevations in CD4 positive lymphocytes in the bronchial mucosa, an abnormality that is also described in sarcoidosis. In general, sarcoidosis and SjD are differentiated by the preponderance of noncaseating granulomata found on biopsy specimens from patients with sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Histopathology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H603381205">
         <span class="h2">
          IgG4-related disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgG4-related disease, also known as IgG4-related sclerosing disease or hyper-IgG4 disease, is distinct from SjD. Patients with IgG4-related systemic disease experience relatively mild xerophthalmia and xerostomia, although marked lacrimal and salivary gland enlargement may occur.
        </p>
        <p>
         Lung involvement in IgG4-related systemic disease is estimated to occur in 10 percent and pleural involvement in 5 percent [
         <a href="#rid68">
          68
         </a>
         ]. A variety of chest CT presentations have been described, including patchy ground-glass, nodular, and consolidative opacities, and also honeycombing [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         The diagnosis of IgG4-related disease is based on the clinical features, a serum concentration of IgG4 ≥2 times the upper limit of normal (140 mg/dL), and the presence of IgG4 positive cells on histopathology  (
         <a class="graphic graphic_table graphicRef81268" href="/z/d/graphic/81268.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H680863639">
         <span class="h2">
          Other causes of diffuse parenchymal lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other causes of diffuse lung disease that are not associated with SjD, but are generally in the differential diagnosis of ILD, include drug-induced lung disease, hypersensitivity pneumonia, eosinophilic pneumonia, infection, lymphangitic tumor, and hemorrhage. The evaluation of these entities is discussed in the appropriate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4120541588">
         <span class="h1">
          OTHER PULMONARY MANIFESTATIONS OF SJÖGREN'S DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SjD can develop other respiratory complications that present with dyspnea, cough, or abnormal imaging, such as xerotrachea, pulmonary nodular amyloidosis, pulmonary lymphoma, thromboembolic disease, pulmonary arterial hypertension, and pleural disease.
        </p>
        <p class="headingAnchor" id="H3174904890">
         <span class="h2">
          Xerotrachea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with SjD, involvement of the tracheobronchial submucosal glands can lead to excessive dryness of the airway, which usually presents with a nonproductive cough. Pulmonary function tests and radiographic imaging are normal. Examination by flexible bronchoscopy reveals a dry, erythematous mucosa [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3077689141">
         <span class="h2">
          Pulmonary nodular amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary nodular amyloidosis is occasionally described in association with SjD (usually primary Sjögren's disease [pSjD]) [
         <a href="#rid1">
          1,49,71,72
         </a>
         ]. Pulmonary nodular amyloidosis can present with isolated pulmonary nodules, multiple nodules with or without calcification, and sometimes concomitant lung cysts [
         <a href="#rid6">
          6,49,50,71,73-76
         </a>
         ]. Most cases of amyloid associated with SjD are related to the nodular pattern of amyloidosis [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         A lung biopsy with Congo red staining is typically needed to secure a diagnosis of pulmonary nodular amyloidosis. Further study is needed to determine the type of amyloid deposition. Nodules containing lymphocytes, plasma cells and amyloid deposits (identified by Congo red staining showing green birefringence under polarized light) are reported, sometimes adjacent to or in the wall of lung cysts [
         <a href="#rid71">
          71
         </a>
         ]. In a case report and literature review, deposition of AL (lambda or kappa light chain) or AA amyloid occurs in the absence of systemic amyloidosis [
         <a href="#rid49">
          49
         </a>
         ]. Association with lymphoproliferative disease, such as MALT lymphoma, is often noted and confirmed by the presence of monotypic lymphoid cells on immunohistochemical analysis [
         <a href="#rid71">
          71,77-79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Pulmonary disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Tissue biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2191249452">
         <span class="h2">
          Lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lung malignancies most frequently associated with SjD are the non-Hodgkin lymphomas, and among these, the most common is pulmonary marginal zone lymphoma (MZL; also known as MALT lymphoma or BALT lymphoma) [
         <a href="#rid1">
          1
         </a>
         ]. Involvement of the lung by lymphoma occurs in approximately 20 percent of patients with SjD-associated lymphoma [
         <a href="#rid80">
          80
         </a>
         ]. A spectrum of low- to high-grade lymphomas is reported [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2504539103">
         <span class="h2">
          Pulmonary vascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary vascular disease (eg, thromboembolic disease, pulmonary arterial hypertension) should be considered in the differential of SjD complicated by dyspnea.
        </p>
        <p>
         An increased risk of thromboembolic disease has been described in patients with SjD and appears greatest in the first year after diagnosis [
         <a href="#rid81">
          81,82
         </a>
         ]. Venous thromboembolism should be suspected in patients with an acute onset of dyspnea, particularly when the chest radiograph does not suggest ILD. The evaluation and diagnosis of suspected pulmonary embolism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
         Pulmonary arterial hypertension (PAH) should be considered in a patient with more gradual onset of dyspnea when the degree of dyspnea is not well-explained by the extent of ILD on high-resolution computed tomography (HRCT). PAH rarely occurs in the setting of SjD-ILD, typically in patients with Raynaud phenomenon and cutaneous vasculitis [
         <a href="#rid83">
          83
         </a>
         ]. In a review of 28 patients, antinuclear, anti-Ro/SSA, and anti-ribonucleoprotein (RNP) autoantibodies, as well as positive rheumatoid factor and hypergammaglobulinemia, were often present. The evaluation and diagnosis of PAH is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3054184040">
         <span class="h2">
          Pleural disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unilateral and bilateral pleural effusions are rarely reported in patients with SjD [
         <a href="#rid84">
          84-87
         </a>
         ]. Pleuroparenchymal fibroelastosis (PPFE), a form of upper lobe pleural and subpleural lung parenchymal fibrosis that can be associated with usual interstitial pneumonia, has been reported in patients with pSjD [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1557210519">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117117.html" rel="external">
          "Society guideline links: Sjögren's disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sjögren's disease (SjD) can be classified as primary Sjögren's disease (pSjD), in the absence of an associated rheumatic disease or as secondary Sjögren's disease (SjD) when criteria for SjD are met in addition to criteria for an associated rheumatic disease (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or inflammatory myositis). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Nomenclature'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both primary and secondary SjD are associated with a variety of interstitial lung diseases (ILDs). The types of SjD-associated ILD (SjD-ILD) largely mirror the idiopathic interstitial pneumonias: nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), lymphoid interstitial pneumonia (LIP), cryptogenic organizing pneumonia (COP). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The proportion of patients with SjD who develop ILD at some point is estimated to be 10 to 20 percent, although asymptomatic changes on CT are more common. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of SjD-ILD is typically 5 to 10 years after the onset of SjD, although lung disease may occasionally precede the diagnosis of SjD. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presenting manifestations of SjD-ILD include cough (usually nonproductive), chest pain, and dyspnea. Constitutional symptoms may be present; patients may also report Raynaud phenomenon, arthralgias, or rash. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A chest radiograph is typically obtained as part of the initial evaluation of SjD. If ILD is suspected on the basis of cough, dyspnea, audible crackles, or an abnormal chest radiograph, we obtain pulmonary function tests and a high-resolution computed tomography (HRCT) scan. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If not already performed, we obtain laboratory tests to confirm the diagnosis of SjD, including an antinuclear antibody, anti-Ro/SSA and anti-La/SSB antibodies, rheumatoid factor, and immunoglobulin quantification. (See
         <a class="local">
          'Laboratory'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HRCT findings depend on the type of ILD; ground-glass opacities are most common. Other findings may include bronchial wall thickening, bronchiectasis, centrilobular nodules, irregular interlobular thickening, subpleural honeycombing, and thin-walled cysts. (See
         <a class="local">
          'Chest imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main role of bronchoalveolar lavage (BAL) in a patient with SjD and radiographic evidence of ILD is to exclude other causes of interstitial opacities, such as eosinophilic pneumonia, infection, lymphangitic tumor, and hemorrhage. In SjD-ILD, BAL most commonly shows a predominance of lymphocytes, but may show a predominance of neutrophils. (See
         <a class="local">
          'Bronchoalveolar lavage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with known SjD and suspected ILD, the HRCT scan can often guide the need for further diagnostic steps. When the HRCT suggests NSIP or UIP or concomitant air cysts suggest LIP, a clinical diagnosis can often be made. When the HRCT pattern is more nodular or consolidative, a lung biopsy is typically indicated. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of ILD in SjD includes ILDs that present with sicca symptoms or salivary gland involvement (eg, sarcoidosis, IgG4-related systemic disease), ILDs related to the underlying rheumatic disease (eg, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis), drug-induced pneumonitis, and unrelated ILDs (eg, hypersensitivity pneumonitis). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other respiratory complications of SjD include xerotrachea, pulmonary nodular amyloidosis, pulmonary lymphoma, thromboembolic disease, pulmonary arterial hypertension, and pleural disease. (See
         <a class="local">
          'Other pulmonary manifestations of Sjögren's disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H682560598">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel Deheinzelin, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2015; 54:2230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev 2016; 25:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol 2020; 38 Suppl 126:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med 2013; 107:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song MK, Seol YM, Park YE, et al. Pulmonary nodular lymphoid hyperplasia associated with Sjögren's syndrome. Korean J Intern Med 2007; 22:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirajuddin A, Raparia K, Lewis VA, et al. Primary Pulmonary Lymphoid Lesions: Radiologic and Pathologic Findings. Radiographics 2016; 36:53.
          </a>
         </li>
         <li class="breakAll">
          Freemer MM, King TE Jr. Connective tissue disease. In: Interstitial Lung Disease, King TE Jr, Schwarz MI (Eds), BC Decker, Hamilton, Ontario 2003. p.535.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strimlan CV, Rosenow EC 3rd, Divertie MB, Harrison EG Jr. Pulmonary manifestations of Sjögren's syndrome. Chest 1976; 70:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitali C, Tavoni A, Viegi G, et al. Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome. Ann Rheum Dis 1985; 44:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren's syndrome. Clin Chest Med 1998; 19:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol 2017; 36:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe M, Naniwa T, Hara M, et al. Pulmonary manifestations in Sjogren's syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol 2010; 37:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Balzano CD, Touray S, Kopec S. Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors. Chest 2016; 150:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. Chest 1985; 88:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitali C, Viegi G, Tassoni S, et al. Lung function abnormalities in different connective tissue diseases. Clin Rheumatol 1986; 5:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papathanasiou MP, Constantopoulos SH, Tsampoulas C, et al. Reappraisal of respiratory abnormalities in primary and secondary Sjögren's syndrome. A controlled study. Chest 1986; 90:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newball HH, Brahim SA. Chronic obstructive airway disease in patients with Sjögren's syndrome. Am Rev Respir Dis 1977; 115:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairfax AJ, Haslam PL, Pavia D, et al. Pulmonary disorders associated with Sjögren's syndrome. Q J Med 1981; 50:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal I, Fink G, Machtey I, et al. Pulmonary function abnormalities in Sjögren's syndrome and the sicca complex. Thorax 1981; 36:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi JH, Liu HR, Xu WB, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013; 3:e003569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurumagawa T, Kobayashi H, Motoyoshi K. Potential involvement of subclinical Sjögren's syndrome in various lung diseases. Respirology 2005; 10:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong X, Zheng Y, Wang L, et al. Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. Clin Rheumatol 2018; 37:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokosi M, Riemer EC, Highland KB. Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2010; 31:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luppi F, Sebastiani M, Sverzellati N, et al. Lung complications of Sjogren syndrome. Eur Respir Rev 2020; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uffmann M, Kiener HP, Bankier AA, et al. Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001; 16:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis 2000; 59:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer A, Swigris JJ, du Bois RM, et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest 2009; 136:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome. Respir Med 2020; 163:105895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decker P, Moulinet T, Pontille F, et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev 2022; 21:103013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto O, Saita N, Ando M, et al. Two cases of Sjögren's syndrome with multiple bullae. Intern Med 2002; 41:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuyama N, Ashizawa K, Okimoto T, et al. Pulmonary lesions associated with Sjögren's syndrome: radiographic and CT findings. Br J Radiol 2003; 76:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardiner P, Ward C, Allison A, et al. Pleuropulmonary abnormalities in primary Sjögren's syndrome. J Rheumatol 1993; 20:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franquet T, Giménez A, Monill JM, et al. Primary Sjögren's syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol 1997; 169:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koyama M, Johkoh T, Honda O, et al. Pulmonary involvement in primary Sjögren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging 2001; 16:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22 Spec No:S151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egashira R, Kondo T, Hirai T, et al. CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation. Radiographics 2013; 33:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taouli B, Brauner MW, Mourey I, et al. Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. Eur Radiol 2002; 12:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salaffi F, Manganelli P, Carotti M, et al. A longitudinal study of pulmonary involvement in primary Sjögren's syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography. Br J Rheumatol 1998; 37:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999; 58:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome. Ann Am Thorac Soc 2016; 13:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannou S, Toya SP, Tomos P, Tzelepis GE. Cryptogenic organizing pneumonia associated with primary Sjogren's syndrome. Rheumatol Int 2008; 28:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matteson EL, Ike RW. Bronchiolitis obliterans organizing pneumonia and Sjögren's syndrome. J Rheumatol 1990; 17:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WS, Choi KH. Organizing pneumonia with atypical computed tomography findings in Sjögren's syndrome. Int J Rheum Dis 2015; 18:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panchabhai TS, Farver C, Highland KB. Lymphocytic Interstitial Pneumonia. Clin Chest Med 2016; 37:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. Respirology 2010; 15:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamora AC, White DB, Sykes AM, et al. Amyloid-associated Cystic Lung Disease. Chest 2016; 149:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen C, Mekinian A, Uzunhan Y, et al. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome. Autoimmun Rev 2013; 12:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly C, Gardiner P, Pal B, Griffiths I. Lung function in primary Sjögren's syndrome: a cross sectional and longitudinal study. Thorax 1991; 46:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brune J, Emonot A, Wiesendanger T, et al. Syndrome de Gougerot-Sjögren et fibrose pariéto-alvéolare diffuse. A propos de cinq observations. Rev Fr Mal Resp 1976; 4:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziza JM, Kaplan G, Salomon C, Kahn MF. [Severe pulmonary fibrosis disclosing primary Gougerot-Sjögren syndrome. Apropos of 5 cases, 2 of which were fatal]. Ann Med Interne (Paris) 1986; 137:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilsson AM, Aaltonen HL, Olsson P, et al. Mixed Airway and Pulmonary Parenchymal Disease in Patients With Primary Sjögren Syndrome: A 6-year Follow-up. J Rheumatol 2021; 48:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalavanga YA, Constantopoulos SH, Galanopoulou V, et al. Alveolitis correlates with clinical pulmonary involvement in primary Sjögren's syndrome. Chest 1991; 99:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalavanga YA, Voulgari PV, Georgiadis AN, et al. Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome. Rheumatol Int 2006; 26:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatron PY, Wallaert B, Gosset D, et al. Subclinical lung inflammation in primary Sjögren's syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum 1987; 30:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 2013; 8:e73774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamadori I, Fujita J, Bandoh S, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren's syndrome. Rheumatol Int 2002; 22:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AS, Scofield RH, Hammitt KM, et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest 2021; 159:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anai S, Kumazoe H, Wakamatsu K, et al. [Reversed halo sign in organizing pneumonia secondary to Sjögren syndrome]. Nihon Kokyuki Gakkai Zasshi 2011; 49:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonami H, Matoba M, Yokota H, et al. CT and MR findings of bilateral lacrimal gland enlargement in Sjögren syndrome. Clin Imaging 2002; 26:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiuchi Y, Hakugawa J, Shimizu K, et al. Massive cutaneous follicular lymphoid hyperplasia in a patient with the Sjögren syndrome: 7-year follow-up and immunohistochemical study. Rheumatol Int 2006; 26:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ooms V, Decupere M, Lerut E, et al. Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sjögren syndrome. Am J Kidney Dis 2005; 46:e75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Brito-Zerón P, García-Carrasco M, Font J. Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore) 2004; 83:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi H, Shimokawaji T, Kanoh S, et al. IgG4-positive pulmonary disease. J Thorac Imaging 2007; 22:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constantopoulos SH, Drosos AA, Maddison PJ, Moutsopoulos HM. Xerotrachea and interstitial lung disease in primary Sjogren's syndrome. Respiration 1984; 46:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeong YJ, Lee KS, Chung MP, et al. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr 2004; 28:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlat A, Decaux O, Gervais R, et al. Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association. Amyloid 2009; 16:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbone R, Cosso C, Cimmino MA. Pulmonary nodular amyloidosis in Sjögren syndrome. J Rheumatol 2015; 42:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura S, Miyazaki Y, Mihar T, et al. [A case of multiple nodular pulmonary amyloidosis complicated with primary Sjogren syndrome]. Nihon Kokyuki Gakkai Zasshi 2007; 45:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Ko YC, Jeong JP, et al. Single Nodular Pulmonary Amyloidosis: Case Report. Tuberc Respir Dis (Seoul) 2015; 78:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi H, Matsuoka R, Kitamura S, et al. Sjögren's syndrome with multiple bullae and pulmonary nodular amyloidosis. Chest 1988; 94:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura N, Yamada G, Itoh T, et al. Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjögren's syndrome. Intern Med 2002; 41:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoor A, Colby TV. Amyloidosis of the Lung. Arch Pathol Lab Med 2017; 141:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milani P, Basset M, Russo F, et al. The lung in amyloidosis. Eur Respir Rev 2017; 26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen LA, Prakash UB, Colby TV. Pulmonary lymphoma in Sjögren's syndrome. Mayo Clin Proc 1989; 64:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011; 9:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviña-Zubieta JA, Jansz M, Sayre EC, Choi HK. The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study. J Rheumatol 2017; 44:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogihara T, Nakatani A, Ito H, et al. Sjögren's syndrome with pleural effusion. Intern Med 1995; 34:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teshigawara K, Kakizaki S, Horiya M, et al. Primary Sjogren's syndrome complicated by bilateral pleural effusion. Respirology 2008; 13:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma D, Lu H, Qu Y, et al. Primary Sjögren's syndrome accompanied by pleural effusion: a case report and literature review. Int J Clin Exp Pathol 2015; 8:15322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makimoto G, Asano M, Fujimoto N, et al. Bilateral Pleural Effusions as an Initial Presentation in Primary Sjögren's Syndrome. Case Rep Rheumatol 2012; 2012:640353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enomoto Y, Nakamura Y, Colby TV, et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One 2017; 12:e0180283.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4301 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579729" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099028" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Interstitial lung disease in primary Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26231345" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27246587" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33095142" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Interstitial lung disease in Sjögren's syndrome: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23402779" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Amyloid-associated cystic lung disease in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17939337" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pulmonary nodular lymphoid hyperplasia associated with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26761531" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Primary Pulmonary Lymphoid Lesions: Radiologic and Pathologic Findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26761531" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Primary Pulmonary Lymphoid Lesions: Radiologic and Pathologic Findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/989035" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4026406" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9917960" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28324200" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008923" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pulmonary manifestations in Sjogren's syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27231156" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4017677" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3731715" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lung function abnormalities in different connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3743149" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Reappraisal of respiratory abnormalities in primary and secondary Sjögren's syndrome. A controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/842943" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chronic obstructive airway disease in patients with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7330166" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary disorders associated with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7281097" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pulmonary function abnormalities in Sjögren's syndrome and the sicca complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390161" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24282246" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15691243" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Potential involvement of subclinical Sjögren's syndrome in various lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28748510" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20692541" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulmonary involvement in Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32817113" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lung complications of Sjogren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685093" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10976085" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19429722" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32056839" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34896652" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11868599" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Two cases of Sjögren's syndrome with multiple bullae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14711775" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pulmonary lesions associated with Sjögren's syndrome: radiographic and CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8810621" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8336308" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pleuropulmonary abnormalities in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9275871" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Primary Sjögren's syndrome and associated lung disease: CT findings in 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685094" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pulmonary involvement in primary Sjögren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12376608" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24224588" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12042961" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9566665" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A longitudinal study of pulmonary involvement in primary Sjögren's syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10343542" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26741500" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18379789" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cryptogenic organizing pneumonia associated with primary Sjogren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2359080" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bronchiolitis obliterans organizing pneumonia and Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25545763" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Organizing pneumonia with atypical computed tomography findings in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27514593" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lymphocytic Interstitial Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20546191" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26513525" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Amyloid-associated Cystic Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810977" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2028432" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lung function in primary Sjögren's syndrome: a cross sectional and longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Syndrome de Gougerot-Sjögren et fibrose pariéto-alvéolare diffuse. A propos de cinq observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3706962" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : [Severe pulmonary fibrosis disclosing primary Gougerot-Sjögren syndrome. Apropos of 5 cases, 2 of which were fatal].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32541077" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Mixed Airway and Pulmonary Parenchymal Disease in Patients With Primary Sjögren Syndrome: A 6-year Follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2036821" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Alveolitis correlates with clinical pulmonary involvement in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344933" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3689460" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Subclinical lung inflammation in primary Sjögren's syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24040065" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713361" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Non-neoplastic pulmonary lymphoid lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111081" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075377" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22073620" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : [Reversed halo sign in organizing pneumonia secondary to Sjögren syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12427434" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : CT and MR findings of bilateral lacrimal gland enlargement in Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625338" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Massive cutaneous follicular lymphoid hyperplasia in a patient with the Sjögren syndrome: 7-year follow-up and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16253713" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028962" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21107087" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : IgG4-related disease: a cross-sectional study of 114 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18043395" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : IgG4-positive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6494625" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Xerotrachea and interstitial lung disease in primary Sjogren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15538150" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636991" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25554807" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pulmonary nodular amyloidosis in Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17491316" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : [A case of multiple nodular pulmonary amyloidosis complicated with primary Sjogren syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26508930" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Single Nodular Pulmonary Amyloidosis: Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3396429" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Sjögren's syndrome with multiple bullae and pulmonary nodular amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11993793" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28134587" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Amyloidosis of the Lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28877975" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The lung in amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2796402" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pulmonary lymphoma in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21219637" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28298559" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873760" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563128" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Sjögren's syndrome with pleural effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18197929" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Primary Sjogren's syndrome complicated by bilateral pleural effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26823888" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Primary Sjögren's syndrome accompanied by pleural effusion: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23198246" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Bilateral Pleural Effusions as an Initial Presentation in Primary Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28666014" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
